(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide has been researched along with sildenafil citrate in 1 studies
| Studies ((e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide) | Trials ((e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide) | Recent Studies (post-2010) ((e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide) | Studies (sildenafil citrate) | Trials (sildenafil citrate) | Recent Studies (post-2010) (sildenafil citrate) |
|---|---|---|---|---|---|
| 85 | 0 | 65 | 5,862 | 956 | 2,319 |
| Protein | Taxonomy | (e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide (IC50) | sildenafil citrate (IC50) |
|---|---|---|---|
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.0036 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfulaij, N; Horton, JS; Kurokawa, T; Mori, Y; Shiraishi, T; Small-Howard, AL; Stokes, AJ; Turner, HC | 1 |
1 other study(ies) available for (e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide and sildenafil citrate
| Article | Year |
|---|---|
"TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure".
Topics: Acrylamides; Administration, Oral; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cardiomegaly; Heart Failure; HEK293 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Signal Transduction; Sildenafil Citrate; TRPV Cation Channels | 2019 |